Boncz Imre, Donkáné Verebes Eva, Oberfrank Ferenc, Kásler Miklós
Pécsi Tudományegyetem, Egészségtudományi Kar Egészség-gazdaságtani, Egészségpolitikai és Egészségügyi Menedzsment Tanszék 7621 Pécs Vörösmarty u. 4. Országos Onkológiai Intézet, Budapest.
Magy Onkol. 2010 Dec;54(4):283-8. doi: 10.1556/MOnkol.54.2010.4.2.
The aim of our study is to analyse the health insurance reimbursement of oncology drugs in outpatient care, inpatient care and named patient system. Data were derived from the database of the National Health Insurance Fund Administration (OEP). The analysis covers data of pharmaceuticals with health insurance reimbursement between 1 January and 31 December, 2008. We performed the analysis according to the ATC group "L" and ICD codes C00-C99 and D00-D48. Within "L" ATC group, for ICD codes C00-C99 and D00-D48 the annual health insurance expenditure for outpatient and named patient drugs were 36.3 billion Hungarian Forints (HUF) (144.5 million EUR, 211.3 million USD). For drugs used in the acute inpatient care, we found 22.59 billion HUF (89.9 million EUR, 131.5 million USD) annual health insurance expenditure. The Hungarian National Health Insurance Fund Administration (OEP) spent altogether 58.9 billion HUF (234.4 million EUR, 342.8 million USD) for the reimbursement of oncological drugs in outpatient, named patient and inpatient care. The reimbursement of oncological drugs represents a significant expenditure for the Hungarian National Health Insurance Fund Administration (OEP). Boncz I, Donka-Verebes É, Oberfrank F, Kásler M. Assessment of annual health insurance reimbursement of oncology drugs in Hungary.
我们研究的目的是分析肿瘤药物在门诊、住院及特殊患者用药制度下的医疗保险报销情况。数据来源于国家健康保险基金管理局（OEP）的数据库。该分析涵盖了2008年1月1日至12月31日期间有医疗保险报销的药品数据。我们根据解剖学治疗学及化学分类系统（ATC）的“L”组以及国际疾病分类代码（ICD）C00 - C99和D00 - D48进行分析。在“L” ATC组内，针对ICD代码C00 - C99和D00 - D48，门诊和特殊患者用药的年度医疗保险支出为363亿匈牙利福林（1.445亿欧元，2.113亿美元）。对于急性住院治疗中使用的药物，我们发现年度医疗保险支出为225.9亿匈牙利福林（8990万欧元，1.315亿美元）。匈牙利国家健康保险基金管理局（OEP）在门诊、特殊患者及住院治疗的肿瘤药物报销方面总共支出了589亿匈牙利福林（2.344亿欧元，3.428亿美元）。肿瘤药物的报销对于匈牙利国家健康保险基金管理局（OEP）而言是一项重大支出。邦茨·I、东卡 - 韦赖贝斯·埃、奥伯弗兰克·F、卡斯勒·M。匈牙利肿瘤药物年度医疗保险报销评估。
